Brean Capital Remains Bullish on Syneron Medical Ltd (ELOS) Following UltraShape User Experience in Asia

Brean Capital maintained a Buy rating and $13.00 price target on Syneron Medical (NASDAQ: ELOS) as the company pushes UltraShape devices into the European and Asian markets. Brean's thesis on Syneron has not changed. It is an under-valued story and it is believe that if the international business continues its growth momentum into Q2/Q3/Q4 owing to body-related products.

Analyst Difei Yang commented, "As Syneron pushes its UltraShape devices into the European and Asian markets, we thought it is relevant to share the primary research we did during October, 2015 with doctors in Asia. The takeaway is that the doctors had very satisfactory results with UltraShape. Because of Syneron's stronger commercial presence internationally, it is likely for UltraShape to fare better overseas than in the US. Given the extremely low valuation, we would be buyers as the company makes progress towards an ex-US launch."

For an analyst ratings summary and ratings history on Syneron Medical click here. For more ratings news on Syneron Medical click here.

Shares of Syneron Medical closed at $7.22 yesterday.

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Boeing (BA) PT Lowered to $240 at Stifel
• Boston Scientific (BSX) PT Raised to $80 at BTIG